Literature DB >> 20607395

Inhibitory effects of Lang-du extract on the in vitro and in vivo growth of melanoma cells and its molecular mechanisms of action.

Liping Wang1, Huiying Duan, Yishan Wang, Kun Liu, Peng Jiang, Zhen Qu, Kazumi Yagasaki, Guoying Zhang.   

Abstract

The purpose of this study is to investigate the effects of Lang-du extract (LDE) from Traditional Chinese Medicine (TCM) Euphorbia fischeriana Steud on the in vitro and in vivo growth of melanoma cells and its molecular mechanisms of action. Our present results have shown that LDE significantly suppressed the in vitro melanoma cell growth in dose- and time-dependent manners. LDE also displayed the synergistic effect with γ-radiation on the reduction of the cell viability in melanoma cells. The animal experimental results further confirmed that compared with the control group without drug treatment, the tumor volume in mice was significantly and time-dependently less in LDE group. The absolute weight of solid tumor in the LDE group was 7-fold lower than that in the control group. Western blot analysis indicated that LDE markedly down-regulated the expression of anti-apoptotic protein Bcl-2 and up-regulated the level of pro-apoptotic protein Bax, eventually leading the reduction of Bcl-2/Bax protein ratios both in the cultured melanoma cells and in the tumors from melanoma-bearing mice. In addition, LDE significantly reduced the tumor progression-associated protein levels of vascular endothelial growth factor (VEGF), hepatocyte growth factor/scatter factor (HGF/SF), and osteopontin (OPN) in tumors from the LDE-treated mice. Our findings suggest that LDE may have a wide therapeutic and/or adjuvant therapeutic application in the treatment of melanoma and other cancer.

Entities:  

Year:  2010        PMID: 20607395      PMCID: PMC2978309          DOI: 10.1007/s10616-010-9283-z

Source DB:  PubMed          Journal:  Cytotechnology        ISSN: 0920-9069            Impact factor:   2.058


  48 in total

1.  Proapoptotic BAX and BAK: a requisite gateway to mitochondrial dysfunction and death.

Authors:  M C Wei; W X Zong; E H Cheng; T Lindsten; V Panoutsakopoulou; A J Ross; K A Roth; G R MacGregor; C B Thompson; S J Korsmeyer
Journal:  Science       Date:  2001-04-27       Impact factor: 47.728

Review 2.  Melanocyte receptors: clinical implications and therapeutic relevance.

Authors:  J Andrew Carlson; Gerald P Linette; Andrew Aplin; Bernard Ng; Andrzej Slominski
Journal:  Dermatol Clin       Date:  2007-10       Impact factor: 3.478

3.  Induction of apoptosis in K562 cells by jolkinolide B.

Authors:  Huiying Luo; Aiqin Wang
Journal:  Can J Physiol Pharmacol       Date:  2006-10       Impact factor: 2.273

Review 4.  Osteopontin: it's role in regulation of cell motility and nuclear factor kappa B-mediated urokinase type plasminogen activator expression.

Authors:  Riku Das; Subha Philip; Ganapati H Mahabeleshwar; Anuradha Bulbule; Gopal C Kundu
Journal:  IUBMB Life       Date:  2005-06       Impact factor: 3.885

5.  Induction of apoptosis and cell cycle arrest in cancer cells by in vivo metabolites of teas.

Authors:  G Zhang; Y Miura; K Yagasaki
Journal:  Nutr Cancer       Date:  2000       Impact factor: 2.900

6.  Inhibition of NF-kappaB activity decreases the VEGF mRNA expression in MDA-MB-231 breast cancer cells.

Authors:  Arihiro Shibata; Takashi Nagaya; Tsuneo Imai; Hiroomi Funahashi; Akimasa Nakao; Hisao Seo
Journal:  Breast Cancer Res Treat       Date:  2002-06       Impact factor: 4.872

7.  NF- kappa B2/p100 induces Bcl-2 expression.

Authors:  P Viatour; M Bentires-Alj; A Chariot; V Deregowski; L de Leval; M-P Merville; V Bours
Journal:  Leukemia       Date:  2003-07       Impact factor: 11.528

Review 8.  Novel therapeutic inhibitors of the c-Met signaling pathway in cancer.

Authors:  Joseph Paul Eder; George F Vande Woude; Scott A Boerner; Patricia M LoRusso
Journal:  Clin Cancer Res       Date:  2009-03-24       Impact factor: 12.531

Review 9.  Osteopontin as a target for cancer therapy.

Authors:  Nicholas I F Johnston; Vignesh Kumar Gunasekharan; Amod Ravindranath; Ciara O'Connell; Patrick G Johnston; Mohamed K El-Tanani
Journal:  Front Biosci       Date:  2008-05-01

Review 10.  The PTEN, Mdm2, p53 tumor suppressor-oncoprotein network.

Authors:  Lindsey D Mayo; David B Donner
Journal:  Trends Biochem Sci       Date:  2002-09       Impact factor: 13.807

View more
  5 in total

1.  In vitro anti-cancer activity of chamaejasmenin B and neochamaejasmin C isolated from the root of Stellera chamaejasme L.

Authors:  Chong Zhang; Shuang-shuang Zhou; Lin-yi Feng; Da-yong Zhang; Neng-ming Lin; Li-huang Zhang; Jian-ping Pan; Jun-bo Wang; Jie Li
Journal:  Acta Pharmacol Sin       Date:  2012-12-10       Impact factor: 6.150

2.  Selective fraction of Atractylodes lancea (Thunb.) DC. and its growth inhibitory effect on human gastric cancer cells.

Authors:  Ming Zhao; Qingqing Wang; Zhen Ouyang; Bangxing Han; Wenbing Wang; Yuan Wei; Yan Wu; Bing Yang
Journal:  Cytotechnology       Date:  2013-04-07       Impact factor: 2.058

Review 3.  Anti-Cancer Activities of Diterpenoids Derived from Euphorbia fischeriana Steud.

Authors:  Baiyu Jian; Hao Zhang; Cuicui Han; Jicheng Liu
Journal:  Molecules       Date:  2018-02-11       Impact factor: 4.411

4.  Inhibitory effects of neochamaejasmin B on P-glycoprotein in MDCK-hMDR1 cells and molecular docking of NCB binding in P-glycoprotein.

Authors:  Lanying Pan; Haihong Hu; Xiangjun Wang; Lushan Yu; Huidi Jiang; Jianzhong Chen; Yan Lou; Su Zeng
Journal:  Molecules       Date:  2015-02-11       Impact factor: 4.411

5.  Chamaejasmin B exerts anti-MDR effect in vitro and in vivo via initiating mitochondria-dependant intrinsic apoptosis pathway.

Authors:  Ya Jie Wang; Qi Li; Hong Bin Xiao; Yu Jie Li; Qing Yang; Xiao Xi Kan; Ying Chen; Xiao Ni Liu; Xiao Gang Weng; Xi Chen; Wei Yan Cai; Yan Guo; He Fei Huang; Xiao Xin Zhu
Journal:  Drug Des Devel Ther       Date:  2015-09-22       Impact factor: 4.162

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.